Surfix’s mission is to advance global health by delivering accurate, accessible, and affordable diagnostic solutions for disease detection and management, specifically in underserved Point-of-Care (POC) testing segments.

To achieve this goal, Surfix has developed a photonic diagnostics platform that delivers exceptional sensitivity, accuracy, and a broad dynamic range. This cutting-edge technology enables diagnostics with precision surpassing traditional laboratory standards – a POCT with beyond lab-level precision.

Driving Healthcare Forward

Surfix’s objective is to continuously enhance the platform, ensuring it remains easy to use while offering reliable and sensitive detection of a wide array of biomarkers. By doing so, Surfix is committed to elevating healthcare standards and making advanced diagnostics accessible globally. 

Obtaining fast and accurate diagnostic results for a patient’s health status can be challenging and complex. Delays in testing can significantly affect the quality of life, societal outcomes, and healthcare resource utilization (HCRU).

Key Statistics:

• > Approximately 70% of medical decisions today rely on laboratory test results.
• > Most tests focus on a single biomarker.
• > Average laboratory test result turnaround time: several days.
• > Average cost per single biomarker test: €40.

It’s time to change the paradigm!

POC testing offers a rapid, decentralized, and cost-effective alternative to traditional lab tests. It simplifies the diagnostic process, making advanced healthcare accessible even in resource-limited settings. 

Point-of-care testing has already reshaped the healthcare landscape and continues to drive transformative change. With the ability to provide immediate results, POC testing empowers better decision-making, enhances patient outcomes, and reduces healthcare costs. 

Surfix co-develops POC tests with its partners, leveraging its innovative photonic diagnostics platform that integrates six state-of-the-art technologies and consists of the following key components:

1. 1. Photonic Biosensor: The core component, featuring a photonic chip and a microfluidic cartridge enhanced           with Surfix’s proprietary nanocoatings.
2. 2. Dedicated Desktop Reader: A compact and efficient device that works seamlessly with the biosensor.

These technologies, each with a proven track record, are unified in Surfix’s platform to make the seemingly impossible possible for POC testing.

Expanding Applications

The platform’s versatility opens doors to breakthroughs in various fields, including:

• > Drug development
• > Antibiotic susceptibility testing
• > Diagnosis and monitoring of diseases such as cancer and cardiovascular conditions

Surfix’s photonic diagnostics platform represents the future of healthcare by making high-precision diagnostics available where and when they are needed most. For more information, please explore our technology and applications pages. 

For more information, please explore our technology page and applications page.